Diego Holanda
@cdiegoholanda
Phase I, sarcoma, and melanoma fellow at Princess Margaret Cancer Centre
ID: 893176565516951552
03-08-2017 18:27:42
55 Tweet
364 Followers
730 Following
Nesse novembro branco, confira e compartilhe o conteúdo educativo sobre #cancerdepulmao em linguagem acessível para pacientes ▶️ 2/3 youtu.be/J9xzE60ShgI via YouTube | Educational content for 🇧🇷 patients in #LCAM #CancerAwareness Gilberto de Castro Junior GBOT Alerta
CDK12 alterations confer an aggressive phenotype to PCa. Our paper describes successful cases treated with DNA damaging therapies and immunotherapies in CDK12-altered mCRPC, potentially stimulating future studies evaluating this combinations. 👇clinical-genitourinary-cancer.com/article/S1558-…
Just out! After 1y of work and one ASCO poster presentation, I’m happy to share our full paper on CV toxicity after ICIs Elsevier | ScienceDirect @ELS_Oncology Denis Jardim Artur Katz Guilherme Harada Diego Holanda sciencedirect.com/science/articl…
Second report of a marked response to crizotinib in a NSCLC harbouring SLC12A2-ROS1 oncogenic fusion. The first one was described by Rodriguez-Antolin and colleagues from @HGregorioM João Alessi, MD Artur Katz luizagadotti Karina Sacardo Diego Holanda Sírio-Libanês
Our paper about the "Interplay between Tumor Mutational Burden and Mutational Profile" is out! Fantastic team Camila Braganca Xavier Diego Holanda Beatriz Awni Eduardo Campos, Joao P Alves Gabriela Der Agopian Guardia Denis Jardim Pedro A.F. Galante 🧬🚴🇧🇷 mdpi.com/1926244 #mdpicancers via Cancers MDPI
Thank you, Cancers MDPI Editorial Office, for sharing our work! Denis Jardim Diego Holanda Beatriz Awni galante_lab Pedro A.F. Galante 🧬🚴🇧🇷 HSL MedOnc Fellows Sírio-Libanês
At #GI23 ASCO you can meet our fellow Zenaide Souza presenting the results from 🇧🇷 real-life data on GEP-NETS treated with #Lu177 including ❇️G3 GEP-NETS data ❇️clinical & nuclear predictive features HSL MedOnc Fellows Sírio-Libanês
Congrats my dear friend Guilherme Harada 👏🏻👏🏻👏🏻 You’re a brilliant medical oncologist and scientist‼️ ⭐️
⏰ Countdown to #ESMO23 ESMO - Eur. Oncology! Meet us on Saturday and check out our work on survival predictors among TMB-low #cancer patients treated with #immunotherapy galante_lab Pedro A.F. Galante 🧬🚴🇧🇷 Diego Holanda Beatriz Awni Denis Jardim
🎬 It’s a wrap on two fantastic days of #LMS discussions and science with international colleagues! Thanks to LeioMyoSarcoma for this yearly round table. Thanks to Gladdy Lab and Albiruni Razak and the Toronto group for hosting us! Thanks to all speakers and participants!
Happy to share our review on the complexity of the TME and perspectives on targeting approaches 🎯 Thank you for the strong team work JIPO Editors Aung Naing, MD Anderson Cancer Center Carlos Torrado & Princess Margaret Cancer Centre Diego Holanda Ana Veneziani Thais Megid | doi.org/10.36401/JIPO-…
📌Happy to share our perspective on uveal melanoma management, just out in ESMO Open With this amazing team Maurício Ribeiro, MD Ian Hirsch 🔗 esmoopen.com/article/S2059-…
Our paper on how we're uniting the cancer research and care communities in Canada to accelerate precision oncology is out in Cancer Cell! Read it now 👇
Paper 2/2 of our pilot prediction model to determine survival probability on #immunotherapy I would like to highlight the potential importance of the HLA-A point mutations in a neoantigen-restricted scenario (TMB-low cohort) MD Anderson Cancer Center Princess Margaret Cancer Centre doi.org/10.1093/oncolo…
